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The human T-cell lymphotropic virus
type 1 (HTLV-1) is an oncogenic retrovi-
rus that is transmitted from mother to
child, particularly through prolonged
breastfeeding; between sexual partners
through unprotected intercourse; and
from donors to recipients through trans-
fusion and transplantation. Thirty-ﬁve
years after its discovery, screening for
HTLV-1 infection is at best patchy and
mostly nonexistent. There are 2 main rea-
sons for this: ﬁrst, the most recent esti-
mate of the prevalence of HTLV-1 is
5–10 million persons worldwide, with
the important caveat that 86% of the
global population is data poor in this re-
gard [1]; second, there is a perception
that disease related to this virus, which
has coexisted with humankind for
60 000 years, is uncommon. Whether
this reputation is justiﬁed requires up-
to-date and reliable sero- and clinical
epidemiology.
The lifetime risk, among carriers, of
adult-T-cell leukemia/lymphoma is 2%–
6% regardless of the region of study. How-
ever, for HTLV-1–associated myelopathy/
tropical spastic paraparesis (HAM/TSP),
more varied risks are reported with strong
hints that, apart from the route of infec-
tion, ethnicity and human leukocyte anti-
gen (HLA) types impact signiﬁcantly on
risk. Furthermore, HTLV-1 has been as-
sociated with a range of other inﬂamma-
torymanifestations affectingmany organs
but particularly eyes, lungs, and thyroid
and with increased susceptibility to
a number of infections, most notably
Strongyloides stercoralis hyperinfestation
syndrome. (Given the high mortality of
this latter condition, it is our policy to
screen all HTLV-1 carriers who have re-
sided in endemic areas for S. stercoralis).
These diseases are much less well recog-
nized even than HAM/TSP, with no data
on incidence or prevalence among carri-
ers. How, then, are we to judge the global
disease burden of HTLV-1 infection?
In this edition of Clinical Infectious
Diseases, Tanajura et al report on a longi-
tudinal study of 414 HTLV-1–infected
individuals in Brazil [2]. There are a
number of striking ﬁndings. First, among
study participants not previously diag-
nosed with HAM/TSP, 18.4% had, at
baseline assessment, symptoms, signs,
and investigations consistent with a deﬁ-
nite diagnosis of HAM/TSP. Second, an
additional 21%, again at baseline, had pos-
sible or probable HAM/TSP on the basis of
having either 1 motor sign consistent with
HAM/TSP or a neurogenic bladder (prob-
able) or a clinical diagnosis of HAM/TSP
without exclusion of other possible diag-
noses (possible). Third, during up to 8
years of follow-up, 5 subjects (all from
the probable HAM/TSP category) were di-
agnosed with deﬁnite HAM, an incidence
of 1.5%. Finally, very high incidences of a
range of neurological symptoms were doc-
umented, particularly sensory, including
upper limb, even though the median per-
person follow-up was only 2 years.
These ﬁndings are notable because
they differ by an order of magnitude
from most previous reports. Using data
from the mid-1980s, Kaplan et al estimat-
ed a 0.25% lifetime risk of HAM in
HTLV-1–infected Japanese individuals,
based on an average of 24.3 new cases re-
ported per year among approximately
794 800 seropositive individuals (3/
100 000 cases per annum) [3]. These
data have undoubtedly affected some
public health decisions outside Japan.
Received 9 March 2015; accepted 10 March 2015; electron-
ically published 27 March 2015.
Correspondence: Graham P. Taylor, MB, DSc, Department of
Medicine, Imperial College, Norfolk Place, London W2 1PG, UK
(g.p.taylor@imperial.ac.uk).
Clinical Infectious Diseases® 2015;61(1):57–8
© The Author 2015. Published by Oxford University Press on
behalf of the Infectious Diseases Society of America. This is
an Open Access article distributed under the terms of the
Creative Commons Attribution-NonCommercial-NoDerivs
licence (http://creativecommons.org/licenses/by-nc-nd/4.0/),
which permits non-commercial reproduction and distribution of
thework, in anymedium, provided theoriginalwork is not altered
or transformed in anyway, and that thework is properly cited. For
commercial re-use, please contact journals.permissions@oup.
com.
DOI: 10.1093/cid/civ231
EDITORIAL COMMENTARY • CID 2015:61 (1 July) • 57
 at Im







However, in the Caribbean, Murphy et al
diagnosed myelopathy in 0.5% of HTLV-
1 carriers in a case-control study [4],
whereas Maloney et al estimated the life-
time risk of HAM/TSP at 1.9% with an
age-standardized annual incidence of
17.3 per 100 000 infected males and 24.7
per 100 000 infected females [5]. In the
United States, Murphy et al diagnosed my-
elopathy in 2.4% (4/166) newly diagnosed
HTLV-1–infected blood donors [6]; im-
portantly, this study included matched un-
infected controls. Although there is an
extensive literature on the inﬂuence of
HLA types on risk of disease associated
with HTLV-1 infection, especially through
impact on proviral load, and further evi-
dence of ethnic differences based on rates
of HAM/TSP according to tribe in a small
study from Zaire [7], the cross-sectional
prevalence reported from Brazil suggests a
lifetime risk in this population 10-fold
higher than previously reported. Is this due
togenetics orenvironmentor selectionbias?
The risk of HAM/TSP has been strongly
associated with proviral load and, in par-
ticular, with a cutoff of 1 HTLV-1 DNA
copy per 100 peripheral bloodmononucle-
ar cells (a proviral load of 1%) [8]. The Mi-
yazaki Cohort Study followed almost 2000
persons, among whom 27% were HTLV-1
infected, in a decade-long study and re-
ported paraesthesia, polyuria, and nocturia
to be twice as common among those in-
fected with HTLV-1. However, ﬁnding
no association with HTLV-1 proviral load
or strength of antibody response, they
concluded that HTLV-1 per se was not
causatively associated [9]. Similarly,
Tanajura et al found no association with
the frequency of sensory, bladder, or even
motor symptoms and HTLV-1 proviral
load even though up to 30% of the study
participants developed such symptoms
during follow-up. They did ﬁnd, however,
that carriers with HTLV-1 proviral loads of
>5%weremore likely to have demonstrated
deterioration in expanded disability status
score. Also at baseline, subjects diagnosed
with HAM/TSP had higher median
HTLV-1 proviral load (14.8%) than those
who were initially asymptomatic (2.5%),
with the probable/possible HAM/TSP sub-
set intermediate at 4%. It seems, therefore,
that the proviral load in this cohort may be
higher than in other cohorts that cite a me-
dian of 1% for asymptomatic carriers. Even
so, this does not fully account for the
exceptionally high prevalence and inci-
dence of deﬁnite HAM/TSP as assuming
a lifetime risk of HAM/TSP of up to 3%,
even subjects with proviral loads >1%
have only a 6% lifetime risk.
Because only 59% of the cohort was
identiﬁed through screening, with 32%
self-referred and the remainder identiﬁed
by the neurology service or by having
HTLV-1 in the family, further breakdown
of the data from the blood donors only
would be more comparable with other
studies and potentially contribute to un-
derstanding the role, if any, of selection
bias. In particular, the high rate of sen-
sory symptoms of the upper limbs are dif-
ﬁcult to explain from previous reports of
HAM/TSP and raise various possibilities,
including overreporting by study partici-
pants and the presence of additional fac-
tors or alternative etiologies.
It is difﬁcult to comment on the contri-
bution of environment (clinic and com-
munity), but there is now an urgent
need to test these ﬁndings in a new
study with HTLV-1–uninfected matched
controls. If conﬁrmed, at least in some in-
fected communities, the disease burden
of HTLV-1 is considerably higher than
previously reported, and this should
stimulate broader and more effective pre-
vention programs and greater interest
and ﬁnancial support for research into
the treatment of HAM/TSP.
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